

Reference:	FOI.6777.21
Subject:	Gastroenterology biologic medications
Date of Request:	27 August 2021

Requested:

1. How many patients were treated in July 2021 (or latest available month) by the gastroenterology department with the following drugs:
 - Adalimumab (any brand or biosimilar)
 - Infliximab (any brand or biosimilar)
 - Ustekinumab (Stelara)
 - Vedolizumab (Entyvio)
 - Tofacitinib (Xeljanz)
 - Filgotinib (Jyseleca)

2. How many patients were treated in July 2021 (or latest available month) for Crohn's Disease ONLY with the following drugs:
 - Adalimumab (any brand or biosimilar)
 - Infliximab (any brand or biosimilar)
 - Ustekinumab (Stelara)
 - Vedolizumab (Entyvio)

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested for question 2, as it is estimated that the cost of answering your request would exceed the "appropriate limit" as stated in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. The "appropriate limit" represents the estimated cost of one person spending 18 hours (or 2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the information requested, the UHB would need to undertake a manual trawl of patient records and cross reference with the Pharmacy and system, to identify the data requested, as the information is not recorded centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under section 16 of the FoIA, we are required, as a public authority, to provide advice and assistance so far as it is reasonable, to individuals who have made a request under FoIA. Therefore, the UHB provides the information for question 1 below.

1. Hywel Dda University Health Board (UHB) provides, within the table below the number of gastroenterology patients, treated with the listed medications, from 1 to 31 July 2021.

Medication	Number of patients
Adalimumab (any brand or biosimilar)	68
Infliximab (any brand or biosimilar)	41
Ustekinumab (Stelara)	31
Vedolizumab (Entyvio)	40
Tofacitinib (Xeljanz)	*
Filgotinib (Jyseleca)	0

Where the figure in the table has been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018/General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 define personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.